PHIO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	116 465
Gjennomsnittsvolum	417 803
Markedsverdi	3.76M
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.00400 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Kontulis Caitlin	Sell	335	Common stock, $0.0001 par value
2024-02-26	Bitterman Robert J	Buy	2 500	Common stock, $0.0001 par value
2024-02-20	Bitterman Robert J	Sell	1 804	Common stock, $0.0001 par value
2024-02-15	Kontulis Caitlin	Sell	658	Common stock, $0.0001 par value
2024-02-17	Kontulis Caitlin	Sell	523	Common stock, $0.0001 par value

INSIDER POWER
76.89
Last 97 transactions
Buy: 3 139 429 \| Sell: 140 691

Volum Korrelasjon

Lang: -0.17 (neutral)

Kort: -0.99 (very strong negative)

Signal:(46.936) Neutral

Phio Pharmaceuticals Corp Korrelasjon

10 Mest positive korrelasjoner
GETVV	0.915
ATEX	0.811

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Phio Pharmaceuticals Corp Korrelasjon - Valuta/Råvare

-0.44
( neutral )

0.14
( neutral )

0.00
( neutral )

0.68
( moderate )

-0.48
( neutral )

Phio Pharmaceuticals Corp Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-184 000 (0.00 %)
EPS:	$-5.20

FY	2023
Omsetning:	$0
Bruttogevinst:	$-184 000 (0.00 %)
EPS:	$-5.20

FY	2022
Omsetning:	$0
Bruttogevinst:	$-193 000 (0.00 %)
EPS:	$-9.95

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-12.43

Financial Reports:

No articles found.

Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Sanntidsoppdatering for Phio Pharmaceuticals Corp [PHIO]

Upcoming Earnings Alert